REFRACTORY MELANOMA
Clinical trials for REFRACTORY MELANOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MELANOMA trials appear
Sign up with your email to follow new studies for REFRACTORY MELANOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cocktail of cancer drugs targets brain metastases in melanoma patients
Disease control OngoingThis Phase 2 trial tests whether combining bevacizumab (Avastin) with atezolizumab (Tecentriq), with or without cobimetinib (Cotellic), can shrink or control melanoma that has spread to the brain. The study enrolls 29 adults with untreated brain metastases who are not taking ster…
Matched conditions: REFRACTORY MELANOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Precision drug tipifarnib targets rare HRAS cancers in kids
Disease control OngoingThis study tests a drug called tipifarnib in children and young adults (ages 1 to 21) whose cancers have a specific change in the HRAS gene. The cancers are advanced or have come back after treatment. The goal is to see if tipifarnib can shrink tumors or stop them from growing. A…
Matched conditions: REFRACTORY MELANOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug cocktail aims to starve and attack tumors in advanced cancers
Disease control OngoingThis early-phase trial tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ziv-aflibercept (which cuts off blood supply to tumors)—in people with advanced solid tumors like melanoma, colorectal, ovarian, and kidney cance…
Matched conditions: REFRACTORY MELANOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo tackles tough melanoma
Disease control OngoingThis phase II trial is testing whether a combination of two drugs, rigosertib and pembrolizumab, can help people with advanced melanoma that no longer responds to standard immunotherapy. The study involves 7 participants with unresectable or metastatic melanoma. The goal is to se…
Matched conditions: REFRACTORY MELANOMA
Phase: PHASE2 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Last-Resort drug made available for Tough-to-Treat melanoma
Disease control NO_LONGER_AVAILABLEThis program offers vidutolimod (CMP-001) to people with refractory melanoma who have run out of standard options. It is a compassionate use access, not a clinical trial, so it is only available when no other treatments are left. The goal is to provide a potential therapy for tho…
Matched conditions: REFRACTORY MELANOMA
Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC